Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to email@example.com so that we can defer those challenges. Your health and safety are paramount to us.
Posted 14 March 2012 | By Alexander Gaffney, RAC
Pharmaceutical manufacturer AstraZeneca filed a lawsuit on 13 March seeking an injunction against the US Food and Drug Administration (FDA) to bar it from allowing generic versions of its blockbuster antipsychotic drug Seroquel to be marketed in the US.
FDA denied two Citizen Petitions from AstraZeneca on 9 March that requested FDA delay market entry for any generic products not containing the exact warnings contained on the reference listed drug (RLD).
FDA said in its decision that it would not comment on AstraZeneca's claims except to say it's "decision to approve or not approve a specific application will be based on the particular facts that are applicable to that application at the time of the decision."
In its lawsuit, AstraZeneca referenced its arguments made in the Citizen Petitions, particularly "regarding labeling requirements for generic copies of innovative medicines, as well as data exclusivity rights granted to innovative companies that conduct new clinical trials."
Generic copies of Seroquel are scheduled for release in late March unless AstraZeneca's injunction is granted.
Reuters - AstraZeneca sues FDA over generic Seroquel
Pharma Times - AZ sues FDA in generic Seroquel dispute
Tags: Seroquel, AstraZeneca, Delay, Lawsuit, Injunction, Generic, Citizen Petition, Latest News, Patent
Regulatory Focus newsletters
All the biggest regulatory news and happenings.